What Are the Prospects for Inovio's COVID Vaccine?

Inovio Pharmaceuticals (NASDAQ: INO) is one of several companies that lag behind the leaders in the COVID-19 vaccine race. The biotech is currently evaluating its COVID-19 vaccine candidate INO-4800 in a phase 2 study. In this Motley Fool Live video recorded on March 3, 2021, Fool.com contributors Keith Speights and Brian Orelli discuss what the prospects for Inovio's COVID vaccine might be.

Continue reading

Source Fool.com